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The three-dimensional structure of the Sulfolobus solfataricus
serine:pyruvate aminotransferase has been determined to
1.8 A˚ resolution. The structure of the protein is a homodimer
that adopts the type I fold of pyridoxal 50-phosphate (PLP)-
dependent aminotransferases. The structure revealed the PLP
cofactor covalently bound in the active site to the active-site
lysine in the internal aldimine form. The structure of the
S. solfataricus enzyme was also determined with an amino
form of the cofactor pyridoxamine 50-phosphate bound in the
active site and in complex with gabaculine, an aminotrans-
ferase inhibitor. These structures showed the changes in the
enzyme active site during the course of the catalytic reaction.
A comparison of the structure of the S. solfataricus enzyme
with that of the closely related alanine:glyoxylate amino-
transferase has identified structural features that are proposed
to be responsible for the differences in substrate specificity
between the two enzymes. These results have been comple-
mented by biochemical studies of the substrate specificity and
thermostability of the S. solfataricus enzyme.
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pyruvate aminotransferase,
holoenzyme, 3zrp; complex
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1. Introduction
The aminotransferases (transaminases; EC 2.6.1.–) catalyse
the transfer of an amino group from an amino acid to a keto
acid (Mehta et al., 1993). They use the cofactor pyridoxal
50-phosphate (PLP), the biologically active form of vitamin B6,
which is one of nature’s most versatile cofactors (Braunstein &
Shemyakin, 1953; Metzler et al., 1954). The PLP normally
covalently binds to an active-site lysine via a Schiff base
(internal aldimine). The mechanism of aminotransferases is
made up of two half-reactions. In the first half-reaction the
donor substrate gives its amino group to the cofactor, resulting
in a keto acid and enzyme-bound pyridoxamine 50-phosphate
(PMP). In the second half-reaction an amino group is trans-
ferred from PMP to an acceptor keto acid, producing an
amino acid and restoring the PLP internal aldimine.
In most organisms, from bacteria (Umbarger et al., 1963) to
mammals (Ichiyama & Greenberg, 1957), serine biosynthesis
proceeds via a phosphorylated pathway. The penultimate step
is catalysed by a specialized phosphoserine:-ketoglutarate
aminotransferase (EC 2.6.1.52). A nonphosphorylated serine-
degradation pathway also exists in animals (Walsh & Sallach,
1966) and plants (Liepman & Olsen, 2001) in which the amino
group is added or removed by serine:pyruvate aminotrans-
ferase (EC 2.6.1.51; SPAT) or serine:glyoxylate aminotrans-
ferase (EC 2.6.1.45) (Sallach, 1956). Serine aminotransferases
are also found in some bacteria (Izumi et al., 1990). Proteins
related to eukaryotic SPATs are found in a number of archaeal
genomes. The true physiological role of these proteins in
archaea is unclear.
SPAT catalyses reversible amino-group transfer between
serine and pyruvate to form alanine and hydroxypyruvate. In
the first half-reaction of SPAT, serine is converted to hydroxy-
pyruvate and the -amino group is transferred to the cofactor
to generate PMP. In the second half-reaction pyruvate is
aminated to form l-alanine and the PLP is regenerated.
SPATs are the least characterized enzymes in group IV of the
aminotransferases (Mehta et al., 1993), which also contains
alanine:glyoxylate aminotransferase and phosphoserine
aminotransferase.
SPATs often have significant activity towards aromatic
amino acids and methionine. Both rat and mouse liver SPATs
prefer phenylalanine as a substrate and show only 33% and
17% relative activity towards serine (Noguchi, Minatogawa
et al., 1978). Human (Okuno et al., 1980), dog, cat (Noguchi,
Okuno et al., 1978) and Hyphomicrobium methylovorum
(Izumi et al., 1990) SPATs are more specific for serine. Serine
is a very poor substrate for aromatic amino-acid amino-
transferases (Hayashi et al., 1993) and this, together with the
preference of SPATs for pyruvate over -ketoglutarate as
an acceptor, distinguishes them from aromatic amino-acid
aminotransferases.
The broad substrate range shown by SPATs makes them
promising candidate enzymes for industrial biocatalysis, since
reaction with a -hydroxyl substrate is rare for aminotrans-
ferases. A two-enzyme pathway has been demonstrated for
the enzymatic synthesis of the food-flavour precursor 6-deoxy-
l-sorbose (Hecquet et al., 1996) in which the carbon–carbon
bond-forming enzyme transketolase (Takayama et al., 1997)
utilizes the hydroxypyruvate produced by spinach leaf serine:
glyoxylate aminotransferase. As most bacteria do not have
serine aminotransferases, the search for thermostable SPATs
for biocatalytic applications has largely been confined to the
archaea.
Sulfolobus solfataricus is a thermophilic archaeon isolated
from hot volcanic springs and it grows optimally at 348 K and
pH 3.0–4.5 (De Rosa et al., 1975). Its internal pH is maintained
at 6.5 by the efficient expulsion of protons (Moll & Schaefer,
1988). Its genome sequence (She et al., 2001) shows a potential
SPAT aminotransferase (gi:13815901), which is the subject of
the present study and has 65% sequence identity to a protein
from the related S. tokodaii and 49% sequence identity to the
Picrophilus torridus DSM 9790 SPAT enzyme. The closest
enzymes with known structures are the alanine:glyoxylate
aminotransferases (AGATs) from yeast (Meyer et al., 2005)
and human (Zhang et al., 2003), which share 36 and 30%
sequence identity, respectively. These enzymes are involved in
the degradation of glyoxylate, which is produced during the
breakdown of sugars and amino acids (Rowsell et al., 1972).
This paper describes the characterization of the
S. solfataricus SPAT protein and the structure of the recom-
binant enzyme determined in the holoenzyme (internal aldi-
mine) form, in the PMP-bound form and as a complex with the
inhibitor gabaculine. A structural comparison has been made
with other group IV aminotransferase enzymes and this has
been used to explain the differences in substrate specificity
between S. solfataricus SPAT and the closely related alanine:
glyoxylate aminotransferase (EC 2.6.1.44; AGAT).
2. Methods
2.1. Expression and purification
The SPAT gene (NCBI gi:13815901) was amplified by PCR
from S. solfataricus P2 genomic DNA and inserted into the
pET-21a(+) vector (Novagen, Nottingham, England). The
gene contains an internal NdeI site, which was removed by
overlap extension PCR on the genomic DNA, leaving a new
NdeI site at the N-terminus. The amplified product was cloned
into pET-21a(+) between the NdeI and XhoI sites. An
N-terminal hexahistidine tag containing the sequence MGH-
HHHHH was then added by replacing the DNA between the
XbaI and NdeI sites, forming the final expression plasmid
pQR922. Escherichia coli BL21 (DE3) Rosetta2 [F ompT
hsdSB(rB
 mB
) gal dcm (DE3) pRARE2* (CamR)] (Novagen)
was used as the expression host.
E. coli cells harbouring the pET-21a vector containing the
S. solfataricus SPAT gene were grown in LB medium
containing 100 mg ml1 ampicillin at 303 K. When the OD600
reached 0.8–1.0, isopropyl -d-1-thiogalactopyranoside was
added to 1 mM. After a 3 h induction at 303 K, the cells were
harvested by centrifugation at 12 000g. The cell paste from 1 l
culture was resuspended in 50 mM Tris–HCl pH 7.5 at a
concentration of 10%(w/v). Sonication was carried out using a
Soniprep 150 Sonicator (Sanyo). The lysed cell extract was
incubated at 353 K for 20 min, followed by centrifugation at
12 000g to remove precipitated protein and cell debris.
The hexahistidine-tagged aminotransferase was purified on
a HiLoad nickel column (Pharmacia, Uppsala, Sweden) using
a linear gradient of 0–1M imidazole in a buffer consisting of
50 mM Tris–HCl pH 7.5, 50 mM PLP. The enzyme was further
purified by gel filtration on a Superdex 200 gel-filtration
column (Pharmacia, Uppsala, Sweden) using a buffer
consisting of 50 mM Tris–HCl pH 7.5, 0.1M NaCl, 50 mM PLP.
2.2. Enzyme activity and stability assays
The hydroxypyruvate produced from the turnover of serine
and either pyruvate, glyoxylate or -ketoglutarate was
measured in a sequential assay. Initially, an aminotransferase
reaction was carried out at 310 K in 50 mM Tris–HCl pH 7.3,
40 mM PLP and 5 mM (substrate assay) or 10 mM (stability
assay) of each substrate. A small sample (2–20 ml) was then
added to 200 ml of an assay solution consisting of 0.11 mg ml1
2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-tetra-
zolium (WST-1; Dojindo Laboratories, Kumamoto, Japan) and
0.1M NaOH (final concentrations are given). The blue colour
of the resulting WST-1 formazan was quantified by measuring
its absorbance at 600 nm.
The catalytic pH optimum was determined by the above
method using 50 mM sodium citrate (pH 2.5–6.6), potassium
phosphate (pH 6.3–7.8) or sodium borate (pH 8.1–10.1) buffer
in place of Tris–HCl.
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For stability assays, the aminotransferase (0.4 mg ml1) was
first incubated in 50 mM of the above citrate/phosphate/
borate buffers, 100 mM PLP, 2 mM pyruvate and 1 mg ml1
bovine serum albumin at 323–262 K for 10 min before 1:4
dilution into 200 mM Tris–HCl buffer pH 7.3 for the amino-
transferase assay, which was carried out at 310 K.
Turnover of all other amino-acid substrates was determined
indirectly by measurement of the alanine produced from the
amino acceptor pyruvate in a coupled assay. The reaction
contained 100 mM potassium phosphate pH 8.0, 5 mM of the
amino-acid substrate, 5 mM pyruvate, 40 mM PLP, 15 mM
NAD (pH adjusted to 8.0), 5 mM 1-methoxy-5-methylphena-
zine methylsulfate (Dojindo), 0.3 mM 2,3-bis-(2-methoxy-
4-nitro-5-sulfophenyl)-tetrazolium-5-carboxanilide (XTT;
Biotium, Hayward, California, USA), 1 U ml1 Bacillus
subtilis alanine dehydrogenase (Sigma–Aldrich, Gillingham,
England) and 0.01–0.1 mg ml1 aminotransferase. The absor-
bance of the XTT-formazan produced was measured at
470 nm.
2.3. S. solfataricus SPAT crystallization
Initial crystallization was carried out with crystal screens
from Molecular Dimensions by the microbatch method using
an Oryx robot (Douglas Instruments). The volume of the
droplet was 2 ml, consisting of 1 ml protein sample and 1 ml
screening condition. Cocrystallization of S. solfataricus SPAT
was carried out in the presence of 10 mM gabaculine
(5-amino-1,3-cyclohexadienyl carboxylic acid) and 20 mM
phenylalanine, one of the amino-donor substrates. These
cocrystallizations were performed using the same crystal
screens.
The best holoenzyme crystals were grown using a final
concentration of 5 mg ml1 protein, 50 mM Tris–HCl buffer
pH 8.5 and 15% PEG 400 at 293 K. The crystals of the PMP
and gabaculine complexes were grown using different condi-
tions of PEG in the crystal screens. The crystallization
conditions of the crystal used to collect data for the gabaculine
complex contained 200 mM calcium chloride.
2.4. Data collection and processing
Excess liquid was removed under silicone oil from crystals
extracted directly from crystallization droplets for the holo-
enzyme and PMP complex before cooling. Glycerol was added
to the microbatch droplet of the gabaculine-cocrystallized
protein to 20%(v/v) before the crystal was frozen.
X-ray diffraction data were collected from the holoenzyme
and the gabaculine–SPAT crystals on an in-house source at a
temperature of 100 K using a MAR 345 (MAR Research)
image plate mounted on a rotating-anode generator (Bruker
AXS). The latter was operated at 100 mA and 35 kV (3.5 kW),
producing Cu K radiation, which was collimated using
XENOCS FOX2D CU25_25P mirrors. Data for holoenzyme
SPAT crystals were later re-collected on beamline 14.1 at the
Daresbury Synchrotron at a wavelength of 1.488 A˚. The PMP-
complex data were collected on beamline I03 at the Diamond
Synchrotron at a wavelength of 0.92 A˚. In-house data were
processed using the programs DENZO and SCALEPACK
(Otwinowski & Minor, 2001). Synchrotron data were
processed with MOSFLM (Leslie, 1992).
2.5. Structure determination
The structure of the S. solfataricus SPAT holoenzyme was
determined by the molecular-replacement method using the
in-house S. solfataricus SPAT holoenzyme data and the
BALBES program pipeline (Long et al., 2008) running on the
York Structural Biology Laboratory server. The best solution
was found using the monomer of yeast AGAT (PDB entry
2bkw; Meyer et al., 2005) as a model, which shares 37%
sequence identity with S. solfataricus SPAT. The initial R
factor was 55% and Rfree was 55% for the resulting molecular-
replacement model and the model was refined to an R factor
of 41% and an Rfree of 47%. The resulting model underwent
cycles of isotropic B-factor crystallographic refinement using
the program REFMAC5 (Murshudov et al., 2011) and manual
model building performed in Coot (Emsley & Cowtan, 2004).
Solvent molecules were added using Coot. The two subunits of
each structure were rebuilt independently and refined using
REFMAC5 with local noncrystallographic symmetry (NCS)
constraints. The van der Waals distances were restrained. The
two complex structures were solved by molecular replacement
using the coordinates of the holoenzyme structure.
The program PyMOL (DeLano, 2002) was used for
preparation of the protein structure figures.
2.6. PDB accession codes
The atomic coordinates and structure factors have been
deposited in the PDB with accession codes 3zrp, 3zrq and 3zrr
for the holoenzyme, the PMP complex and the gabaculine
complex, respectively.
3. Results and discussion
3.1. Enzyme substrate specificity
The highest activity for the putative S. solfataricus SPATwas
observed with methionine, the aromatic amino acids phenyl-
alanine and tryptophan and the substituted aromatic amino
acids bromophenylalanine and iodotyrosine. The amino-
donor specificity is therefore similar to that of aromatic amino-
acid aminotransferases (Hayashi et al., 1993; Onuffer et al.,
1995). The dicarboxylic amino acids aspartic acid and glutamic
acid were not found to be substrates of this SPAT, while their
amide analogues asparagine and glutamine were. The amino-
donor substrate specificity for S. solfataricus SPAT is shown in
Fig. 1.
The S. solfataricus enzyme showed a clear preference for
both pyruvate and glyoxylate as amino acceptors in the
presence of the donor serine (data not shown). No activity was
detected towards -ketoglutarate, which is the most frequently
used amino-group acceptor of aminotransferases, including
aromatic amino-acid aminotransferases. The activity towards
serine, which was not observed for aromatic acid amino-
transferases (Hayashi et al., 1993), and the absence of activity
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towards -ketoglutarate allows the classification of the
S. solfataricus enzyme as a serine:pyruvate aminotransferase.
The specific activity of S. solfataricus SPAT towards serine
was much lower than that towards aromatic amino acids. This
is similar to rat and mouse liver serine aminotransferases
(Noguchi et al., 1978). Some activity was also observed
towards homophenylalanine and kynurenine and this is
similar to that found for human SPAT, which has been shown
to also be responsible for kynurenine:glyoxylate amino-
transferase activity (Okuno et al., 1980).
The d-amino acids tested and phospho-l-serine were not
substrates of S. solfataricus SPAT, which is in line with the role
of the enzyme as an l-serine aminotransferase. dl-3-Phenyl-
3-aminopropionate, the -amino-acid analogue of phenyl-
alanine, was not a substrate. An absence of activity towards
-alanine has been reported for rat liver serine aminotrans-
ferase (Oda et al., 1989). An amino alcohol (phenylalaninol)
and an amine (sec-butylamine) were also found not to be
substrates of S. solfataricus SPAT.
The optimal activity of S. solfataricus SPAT has been
determined to be around pH 7.1 when assayed at 310 K using
the serine:pyruvate reaction. At least 75% of the maximum
activity is retained between pH 6.4 and 8.3. The enzyme was
determined to be relatively thermostable. At physiological pH
6.5, S. solfataricus SPATwas stable for 10 min at 343 K, while
half of the initial activity was lost at 353 K.
3.2. Quality of the models
The three S. solfataricus SPAT structures were refined to R
factors of 21.2% to 1.82 A˚ resolution for the holoenzyme
structure, 18.9% to 2 A˚ resolution for
the gabaculine complex and 18.7% to
1.82 A˚ resolution for the PMP complex
using all data in the corresponding
resolution ranges without a  cutoff.
These excluded 5.0% of the randomly
distributed reflections assigned to
calculate the Rfree values, which were
25.6, 23.1 and 23.3%, respectively. The
asymmetric unit of each structure
contained a dimeric SPAT molecule.
The electron density allowed the posi-
tioning of residues 6–382 in both sub-
units out of a total of 384 residues in the
holoenzyme structure. Residues 5–383
were built for both subunits in the
gabaculine-complex structure; in the
PMP-complex structure the terminal
Met1 and Arg384 were not built in both
subunits. Each model also contained
just over 500 water molecules, and the
gabaculine-complex structure contained
four calcium ions. The data-collection
and model-refinement statistics of the
three structures are listed in Table 1.
The dispersion precision indicator
(Murshudov & Dodson, 1997) gives an overall estimate of the
root-mean-square error in the coordinates of 0.14 A˚ for the
holoenzyme structure, 0.13 A˚ for the PMP complex and
0.17 A˚ for the gabaculine complex for the well defined part of
the structure. The overall G-factor is 0.1 for all three refined
structures as calculated by the program PROCHECK
(Laskowski et al., 1993) and was used as a measure of the
stereochemical quality of the model, which is better than
average for the given resolutions. Pro10 is in the cis confor-
mation in the PMP-complex structure. The holoenzyme
structure and the gabaculine complex do not have any
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Table 1
Summary of data-processing and refinement statistics.
Values in parentheses are for the outer resolution shell. The Wilson B factor was estimated by SFCHECK
(Vaguine et al., 1999). Ramachandran plot analysis was performed by PROCHECK (Laskowski et al.,
1993).
Crystal Holoenzyme Gabaculine complex PMP complex
Space group C2 C2 C2
Unit-cell parameters (A˚, ) a = 162.4, b = 55.0,
c = 101.8,  = 111.3
a = 160.8, b = 55.2,
c = 102.3,  = 111.5
a = 160.1, b = 55.1,
c = 101.6,  = 111.0
Wavelength (A˚) 1.488 1.54 0.92
Resolution range (A˚) 43–1.82 (1.92–1.82) 25–2.00 (2.03–2.00) 56.5–1.82 (1.92–1.82)
Completeness (%) 98.2 (94.4) 95.9 (91.9) 99.7 (99.9)
Multiplicity 2.8 (2.5) 2.8 (2.4) 4.1 (4.1)
hI/(I)i 9.6 (2.0) 10.4 (2.0) 9.6 (2.0)
Rmerge† (%) 5.5 (32.3) 8.9 (51.3) 8.0 (63.3)
Rcryst‡ (%) 21.2 18.9 18.7
Rfree (5% of total data) (%) 25.6 23.1 23.3
R.m.s.d. bond length§ (A˚) 0.012 [0.022] 0.012 [0.022] 0.012 [0.022]
R.m.s.d. bond angles§ () 1.25 [1.99] 1.30 [1.99] 1.25 [1.99]
Wilson B factor (A˚2) 39.7 47.1 37.9
Average B factor (A˚2)
Protein 38.8 42.9 38.0
Solvent 45.4 48.6 45.5
Ligand 29.7 39.4 24.1
Ramachandran analysis
(% of residues in
most favoured regions)
94.4 93.1 92.5
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the intensity of reflection hkl,
P
hkl is the sum
over all reflections and
P
i is the sum over i measurements of the reflection. ‡ Rcryst =
P
hkl

jFobsj  jFcalcj

=P
hkl jFobsj. § Target values are given in square brackets.
Figure 1
The activity of S. solfataricus SPAT towards amino substrates (l-isomers
unless stated otherwise). Pyruvate was used as the amino acceptor. The
mean and standard deviation of at least five data points is shown. 5 mM
(0.5 mM for homophenylalanine and 4-bromophenylalanine) of each
amino-donor substrate and 5 mM pyruvate were used.
residues in the cis conformation. 92–94% of the nonglycine
residues fall into the most favourable regions of the Rama-
chandran plot (Ramakrishnan & Ramachandran, 1965) in the
three structures as defined by PROCHECK, with no residues
in the disallowed or generously allowed regions. Approxi-
mately 41% of the amino acids are in -helices, 15% are in -
sheets and less than 2% are in 310-helices.
3.3. Overall structure of S. solfataricus SPAT
The S. solfataricus SPAT monomer consists of two /
domains (Fig. 2): a large PLP-binding N-terminal domain
(residues 2–262) and a smaller C-terminal domain (residues
263–381). The N-terminal domain folds into a typical //
sandwich made up of a central seven-stranded -sheet of
mixed type with direction ++++++ and topology +5x, +1x,
2x,1x,1x,1 in Richardson’s classification (Richardson,
1981). The -sheet is surrounded on both sides by ten
-helices, with no helices between strands S7, S6 and S5. The
loops between these strands are involved in cofactor binding.
The smaller C-terminal domain consists of a four-stranded
antiparallel -sheet with +1, +2, 1 topology and four
-helices on the external side relative to the -sheet.
Size-exclusion chromatographic experiments showed
elution of S. solfataricus SPAT at 90 kDa, suggesting the
presence of dimers in solution, which is consistent with the
oligomeric states of the closest structural homologues. The
asymmetric unit of the crystal contained two tightly bound
subunits forming the functional homodimer. The formation of
the dimer buries 4017 A˚2, which amounts to 23% of the
solvent-accessible surface area of each monomer being buried.
Dimer formation results in the formation of 21 hydrogen
bonds between the two monomers, mainly between the two
N-terminal domains, and contacts between the N-terminal
extension of one subunit and the N-terminal domain of the
opposite subunit. A salt bridge is also formed between Asp222
and Arg98 of each monomer.
Molecular features that are known to contribute to
thermostability include an increased number of hydrogen
bonds and ion pairs, shortening of surface loops, tighter core
packing, increased hydrophobicity and higher oligomeric
states. It appears that both ion-pair interactions and hydro-
phobicity contribute to the thermostability of S. solfataricus
SPAT. In addition to a number of ion pairs, there are three ion-
pair networks close to the surface of the S. solfataricus SPAT
protein, comprising Glu118–Lys115–Asn112–Arg293–Glu295,
Arg270–Glu262–Arg267–His271 and Lys97–Glu93–Arg107–
Asp90. The dimer interface of S. solfataricus SPAT is largely
hydrophobic and is proposed to contribute to the ability of
the enzyme to retain its quaternary structure at elevated
temperatures.
3.4. The active site
The cofactor PLP in the holoenzyme structure is in the
internal aldimine form, in which it is covalently bound to the
active-site Lys189 via a Schiff base (Fig. 3a). The active-site
cleft is formed by the two domains of one monomer and the
large domain of the neighbouring monomer. Residues from
both subunits are involved in cofactor binding, but the
substrate site is formed mainly by residues of the two domains
from one monomer. The cofactor is bound at the bottom of
the active site, with its re side facing the solvent. The active-
site Lys189 residue is located between strands 6 and 7 and
binds on the si face of the cofactor, hiding the lysine from the
solvent. The O atoms of the phosphate group interact with the
main-chain amides of Gly63 and Thr64 and the side chains
of Thr64 and Gln188. The cofactor is firmly anchored by
hydrogen bonding from Thr243 and Tyr240 to the O atoms of
the phosphate group. The carboxyl group of Asp163 is within
hydrogen-bonding distance of the pyridine N atom. Asp163
is kept in place by interactions with the main-chain amide of
residue Val165. The phenol hydroxyl group of the cofactor is
within bonding distance of the side chains of Thr138 and
Ser166. The pyridine ring of PLP is sandwiched between the
side chains of Phe88, which stacks flat against the ring on the
re side, and Val165 from the si side of the ring (Fig. 4). Ivanov
& Karpeisky (1969) suggested that conditions for optimal
operation at each of the sequential steps of the transamination
reaction are provided by structural rearrangements occurring
in a preceding step; the latter involves the reorientation of the
pyridine ring of PLP. Therefore, an attempt was made to
elucidate structures of S. solfataricus SPAT complexes with
substrates and inhibitors in order to monitor the rearrange-
ments in the active site.
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Figure 2
Folding of the S. solfataricus SPAT subunit shown as a ribbon diagram
coloured by secondary structure: -helices are coloured red, -strands
yellow and loops green. The N-terminal segment which changes
conformation between different enzyme states is highlighted in blue.
This figure and Figs. 3–7 were prepared using PyMOL (DeLano, 2002).
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3.5. PMP complex
The structure of the PMP-bound form of the enzyme was
obtained in an attempt to cocrystallize the enzyme–substrate
complex. Cocrystallization of the protein with 20 mM of the
donor substrate phenylalanine failed to produce interpretable
density for the substrate. However, the Schiff base between
the active-site Lys189 and PLP appeared to be broken in the
electron density (Fig. 3b). This would imply that the enzyme
had reacted with the donor substrate in the crystallization
droplet and was trapped in the PMP state owing to the excess
of the donor substrate. A subunit of the holoenzyme structure
can be superimposed with a subunit of the PMP complex with
an r.m.s.d. of 0.35 A˚ for 370 C atoms. No significant structural
differences were observed in the active sites of the two
structures except for a small displacement of the active-site
Lys189 and the phosphate of PLP. No rotation of the pyridine
ring of PLP was observed. This differs from chicken mito-
chondrial aspartate aminotransferase, for which a rotation of
the cofactor pyridine ring of several degrees was observed
between the internal aldimine and PMP-bound forms of the
enzyme (McPhalen et al., 1992). However, one would expect
a close orientation of the pyridine ring at the start of each of
the two transamination half-reactions. The N-termini in the
holoenzyme and the PMP-complex structure adopt a similar
conformation, although they are much better defined in the
PMP-bound structure.
3.6. Gabaculine-inhibited SPAT
Gabaculine is a common suicide inhibitor of both - and
!-aminotransferases. Enzymes that have been reported to be
inhibited by gabaculine include ornithine aminotransferase
(Jung & Seiler, 1978; Shah et al., 1997), !-aminotransferase
(Burnett et al., 1980), 7,8-diaminopelargonic acid synthase
(Mann et al., 2005), 4-aminobutyrate aminotransferase (Kim et
al., 1981), d-amino-acid aminotransferase (Soper & Manning,
1982), alanine aminotransferase and asparagine aminotrans-
ferase (Wood et al., 1979). Gabaculine binds to the amino-
transferase enzyme, forming a Schiff base with the PLP
cofactor. Initial proton abstraction occurs as normal. A second
proton abstraction on the adjacent C atom (C) then occurs,
yielding an unstable intermediate that is converted to
m-carboxyphenylpyridoxamine phosphate (mCPP), which is
Figure 3
2Fo  Fc electron-density maps of the S. solfataricus SPATactive site are shown contoured at 1. (a) Electron-density map of the holoenzyme calculated
at 1.82 A˚ resolution. The Lys189–PLP Schiff base is labelled LLP-189. (b) Electron-density map of the PMP-bound form calculated at 1.82 A˚ resolution,
showing that the covalent link between the cofactor and Lys189 is broken. (c) Electron-density map of the gabaculine complex calculated at 2 A˚
resolution. The nonhydrolysable PLP–gabaculine complex is shown as an mCPP molecule.
extremely stable, resulting in an irreversible aromatic modi-
fication of the cofactor (Rando, 1977; Shah et al., 1997; Fu &
Silverman, 1999). Alanine racemase and tryptophanase, which
do not catalyse the second proton abstraction at C of their
substrates, have been shown to be insensi-
tive towards gabaculine (Soper & Manning,
1982). All previously reported amino-
transferases have been shown to be irre-
versibly inhibited by gabaculine owing to
the nature of the mCPP ligand, which is
tightly bound to the active site of the
enzyme. Release of the mCPP ligand is only
achieved through denaturation of the
protein (Shah et al., 1997).
S. solfataricus SPAT was prepared in a
slight molar excess of gabaculine and was
shown to be completely inhibited after a 1 h
incubation. The experiment was repeated in
the presence of excess PLP and the enzyme
still exhibited no activity, suggesting that the
inhibitor ligand cannot leave the active site,
which is consistent with previously reported
gabaculine aminotransferase inhibition
(Shah et al., 1997; Fu & Silverman, 1999).
The electron density in the enzyme active
site allowed modelling of the cofactor
covalently bound to gabaculine as the irre-
versible mCPP ligand. A 2Fo  Fc electron-
density map for the mCPP ligand and the
active-site lysine is shown in Fig. 3(c). The
carboxyl group of the gabaculine molecule
makes hydrogen bonds to Arg337 with a
length of 3.2 A˚. The gabaculine then
displaces the internal lysine–PLP Schiff base
to form the external aldimine complex with
cofactor, which spontaneously rearranges to
form the nonhydrolysable adduct mCPP.
The gabaculine part of the mCPP molecule
is bound in a hydrophobic pocket formed by
residues Val8, Phe88 and Ala326 from the
PLP-binding subunit and Phe28 and Tyr240
from the neighbouring subunit (Fig. 5a). The
aromatic ring of the gabaculine molecule
stacks against Tyr240 at an approximate
angle of 45 and a distance of 3.7 A˚. These
interactions are strong enough to render the
enzyme inactive and trap the mCPP ligand
in the active site. This is consistent with
other aminotransferase enzymes inhibited
by gabaculine, such as ornithine amino-
transferase (PDB entry 1gbn; Shah et al.,
1997), in which Tyr85 and Phe177 stack on
either side of the gabaculine ring, which is
reported to provide a structural basis for a
dead-end irreversible intermediate.
A comparison of the gabaculine-bound
and holoenzyme structures showed that they
were very similar overall, with an r.m.s.d. of
0.4 A˚ calculated across 370 residues. A
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Figure 5
Binding of the mCPP complex to S. solfataricus SPAT. (a) A stereo diagram showing the
interactions of the gabaculine–PLP complex molecule mCPP bound in the S. solfataricus SPAT
active site. Residues within 4.5 A˚ of the inhibitor are shown. (b) Rearrangement of the
N-terminal residues between the PMP structure and the gabaculine complex. Both molecules
are shown as a grey C trace, except for the N-termini, -sheets of the small domain and the
moving loop 318–325, which are shown in red for the PMP structure and in blue for the
gabaculine complex. The PMP and mCPP molecules are shown as stick models in the same
colours.
Figure 4
The cofactor–protein interactions in the active site of the S. solfataricus SPATholoenzyme. The
stereo diagram shows the residues within 4.5 A˚ of the cofactor. The Lys189–PLP Schiff base is
highlighted as a stick model. Residues from the neighbouring subunit are indicated with an
asterisk.
significant difference in the location of the N-
terminal region of the protein and an adjust-
ment of the adjacent region formed by residues
318–325 located between -helix 11 and strand
3 of the small-domain -sheet is observed
between the two structures. In the PMP-bound
and the holoenzyme structures the N-terminus
folds back at residues 8–11 to form a two-
stranded parallel -sheet with small-domain
residues 323–324. In the gabaculine-complex
structure the N-terminal loop adopts an
extended conformation antiparallel to the
neighbouring strand 3 (residues 326–327) of the
-sheet of the small domain. It folds over the
gabaculine ligand, ‘locking’ the complex in
place and partially shielding the active site from
the bulk solvent (Fig. 5b). It would appear that
this rearrangement of the N-terminus is caused
by binding of the mCPP carboxyl group to
Arg337, leading to a displacement of Val8. This
movement is accompanied by a change in the
conformation of loop 318–325, with displace-
ment of most C positions by 3–5 A˚ towards the
position occupied by the N-terminus in the
holoenzyme and PMP-complex structures.
Interestingly, the complexes of related proteins
with their substrate analogues (PDB entries
2bkw, 1h0c and 1j04; Meyer et al., 2005; Zhang
et al., 2003; Djordjevic et al., 2010) are more
similar to the SPAT holoenzyme structure than
to the SPAT–gabaculine complex.
The bulky donor substrate phenylalanine
was manually positioned in the S. solfataricus
SPAT active site with the carboxy group of the
substrate in the same position as in the gaba-
culine complex. This was orientated for cata-
lysis according to the Dunathan hypothesis
(Dunathan, 1966), positioning the cleaved C—
H bond of the amino acid normal to the plane
of the PLP pyridine ring pointing towards the
active-site Lys189. It appears that steric
restrictions provided by the side chains of
Phe88 and Tyr240 from the adjacent subunit
allow only one single rotamer of the substrate
side chain to fit into the active site (Fig. 6). This
would explain the absence of activity towards
substrates branching at C such as threonine
and -methyl-dl-phenylalanine (Fig. 1), since
these substrates would sterically clash with
aromatic residues within the active site. The
substrate-binding pocket of SPAT is relatively
hydrophobic, which does not favour the
binding of the charged amino-acid side chains
of aspartate and glutamate. This would explain
the absence of activity of SPAT towards these
dicarboxylic amino acids (Fig. 1) and the
inability to use -ketoglutarate as an amino
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Figure 6
A stereo diagram showing the possible binding of the substrate phenylalanine in the
S. solfataricus SPAT active site. This is based on the structure of the gabaculine complex
and the requirement for the scissile C—H bond to be normal to the pyridine ring of PLP.
The three energy-favourable rotamers of phenylalanine are shown as red, yellow and
purple stick models. Arg337, which binds the carboxy group of the substrate, and Phe28
and Tyr240, which sterically prohibit binding of two of the rotamers (purple and yellow),
are labelled.
Figure 7
Comparison of the active sites of SPATand yeast AGAT. (a) Superimposition of the SPAT
enzyme in the region of its active site with yeast AGAT shown as a C trace with the
modelled phenylalanine substrate shown in red. The differences in the loop regions are
highlighted in black (SPAT) and green (AGAT). Ile344 in AGAT and Val329 in SPAT are
shown as stick models and labelled. (b) A stereo diagram showing superposition of the
active sites of the two enzymes as stick models with an allowed rotamer of phenylalanine
(red) modelled in the SPAT (black) active site. Ile344 of AGAT and Val329 of SPAT are
labelled.
acceptor. In conclusion, noncharged amino acids with no
branching at C should be good substrates for the S. solfa-
taricus aminotransferase.
3.7. Structural comparisons
S. solfataricus SPAT shares 36% sequence identity with
yeast AGAT (Meyer et al., 2005; PDB entry 2bkw), with an
r.m.s.d. of 1.33 A˚ calculated across 328 residues. The yeast
AGAT enzyme has been reported to have high substrate
specificity for alanine and glyoxylate, unlike SPAT, which
exhibits a broad amino-acid substrate specificity. The limited
substrate range of the AGAT has previously been attributed
to nonproductive binding of substrates such as serine (Takada
& Noguchi, 1985; Schlo¨sser et al., 2004; Meyer et al., 2005).
The structures of AGATs from human (Zhang et al., 2003),
Anabaena (Han et al., 2005) and mosquito (Han et al., 2006)
have all been reported, and they share 30, 28 and 26%
sequence identity, respectively, with S. solfataricus SPAT. The
human and mosquito enzymes have been reported to be
largely specific for catalysing alanine:glyoxylate transamin-
ation (Zhang et al., 2003; Han et al., 2006) and the structures of
their active sites are similar to that of yeast AGAT.
The substrate-binding pocket of S. solfataricus SPAT is
significantly different from the active sites of some other
enzymes of the family IV aminotransferases, e.g. phospho-
serine aminotransferase (19% sequence identity to SPAT;
PDB entry 3ffr) and selenocysteine -lyase NifS/CsdB (Lima,
2002; 17% sequence identity to SPAT; PDB entry 1kmj). These
aminotransferases have several charged residues at the
substrate-binding site; however, the SPAT substrate-binding
pocket is mainly hydrophobic. The substrate-binding pockets
of AGATs are remarkably similar to that of S. solfataricus
SPAT.
The phenylalanine model was built into the SPATactive site
as previously described and was compared with the super-
imposed yeast AGAT enzyme structure. Most residues in the
vicinity of the modelled substrate are conserved between the
two proteins. The S. solfataricus SPAT enzyme has a signifi-
cantly larger substrate-binding pocket as its loop region
between strands 9 and 10 is two amino acids shorter. This gives
more space for a bulkier substrate to bind compared with the
AGAT enzyme, which is only active towards alanine and
glycine. Ile344 in AGAT occupies the space where larger
substrates would sit in the active site of the SPATenzyme (Fig.
7). The C1 atom of Ile344 is positioned 2.9 A˚ from the C
atom of the modelled substrate, thus hindering the binding of
any amino acid larger than alanine. In the S. solfataricus SPAT
enzyme the corresponding Val329 is positioned further away,
allowing the binding of larger amino acids; the closest atom of
the Val329 side chain is positioned at least 5 A˚ away from the
nearest atom of the modelled substrate.
This paper has described both biochemical and structural
studies of a thermophilic S. solfataricus SPATenzyme and has
provided a greater insight into the structural rearrangements
that occur within the active site of the enzyme during catalysis.
It represents the first structure to be described for a thermo-
philic archaeal enzyme from this relatively unstudied group IV
of aminotransferase enzymes. It has also provided a greater
understanding of substrate specificity, which is of considerable
interest in the utilization of this enzyme in commercial
biocatalysis.
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